Fate Therapeutics (FATE)
NASDAQ:FATE

Fate Therapeutics (FATE) Stock Forecast & Price Target

930 Followers
See the Price Targets and Ratings of:

FATE Analyst Ratings

Strong Buy
10Ratings
8 Buy
2 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Fate
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

FATE Stock 12 Months Forecast

Average Price Target

$72.50
▲(246.72% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Fate Therapeutics in the last 3 months. The average price target is $72.50 with a high forecast of $115.00 and a low forecast of $35.00. The average price target represents a 246.72% change from the last price of $20.91.
Highest Price Target$115.00Average Price Target$72.50Lowest Price Target$35.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Oppenheimer
$90.00
Buy
330.42%
Upside
Reiterated
Fate Therapeutics price target lowered to $90 from $135 at OppenheimerFate Therapeutics price target lowered to $90 from $135 at Oppenheimer
Robert W. Baird
$28.00
Hold
33.91%
Upside
Reiterated
Fate Therapeutics (FATE) Receives a Hold from Robert W. Baird
Truist Financial
$51.00
Buy
143.90%
Upside
Reiterated
Fate Therapeutics (FATE) PT Lowered to $51 at Truist SecuritiesTruist Securities analyst Robyn Karnauskas lowered the price target on Fate Therapeutics (NASDAQ: FATE) to $51.00 (from $75.00) while maintaining a Buy rating.
Piper Sandler
$71.00
Buy
239.55%
Upside
Reiterated
Fate Therapeutics price target lowered to $71 from $113 at Piper SandlerFate Therapeutics price target lowered to $71 from $113 at Piper Sandler
Barclays
$62.00
Buy
196.51%
Upside
Reiterated
Barclays Thinks Fate Therapeutics' Stock is Going to Recover
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

FATE Financial Forecast

FATE Earnings Forecast
Next quarter’s earnings estimate for FATE is -$0.88 with a range of -$1.12 to -$0.56. The previous quarter’s EPS was -$0.86. FATE beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.42% of the time in the same period. In the last calendar year FATE has Outperformed its overall industry.
Next quarter’s earnings estimate for FATE is -$0.88 with a range of -$1.12 to -$0.56. The previous quarter’s EPS was -$0.86. FATE beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.42% of the time in the same period. In the last calendar year FATE has Outperformed its overall industry.
FATE Sales Forecast
Next quarter’s sales forecast for FATE is $19.48M with a range of $1.50M to $50.00M. The previous quarter’s sales results were $14.98M. FATE beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 42.88% of the time in the same period. In the last calendar year FATE has Outperformed its overall industry.
Next quarter’s sales forecast for FATE is $19.48M with a range of $1.50M to $50.00M. The previous quarter’s sales results were $14.98M. FATE beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 42.88% of the time in the same period. In the last calendar year FATE has Outperformed its overall industry.
FATE Analyst Recommendation Trends
In the current month, FATE has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The FATE average analyst price target in the past 3 months is $72.50
In the current month, FATE has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The FATE average analyst price target in the past 3 months is $72.50

FATE Stock Forecast FAQ

What is FATE’s average 12-month price target, according to analysts?
Based on analyst ratings, Fate Therapeutics’s 12-month average price target is $72.50.
    What is FATE’s upside potential, based on the analysts’ average price target?
    Fate Therapeutics has 246.72% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is FATE a Buy, Sell or Hold?
          Fate Therapeutics has a conensus rating of Strong Buy which is based on 8 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Fate Therapeutics’s price target?
            The average price target for Fate Therapeutics is $72.50. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $115.00 ,the lowest forecast is $35.00. The average price target represents 246.72% Increase from the current price of $20.91.
              What do analysts say about Fate Therapeutics?
              Fate Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis